Sailaja Kamaraju1,2, Yushu Shi1, Elizabeth Smith1, Ann B Nattinger1, Purushottam Laud1,3, Joan Neuner1,4. 1. Center for Patient Care and Outcomes Research, Medical College of Wisconsin, Milwaukee, Wisconsin. 2. Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin. 3. Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, Wisconsin. 4. Department of Medicine, Division of General Internal Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Abstract
BACKGROUND: Theoretically, the estrogen deprivation induced by aromatase inhibitors (AIs) might cause ischemic heart disease, but empiric studies have shown mixed results. We aimed to compare AIs and tamoxifen with regard to cardiovascular events among older breast cancer patients outside of clinical trials. We hypothesized that AIs increase the risk of myocardial infarction. METHODS: We identified women age ≥67 years diagnosed with breast cancer from June 30, 2006 to June 1, 2008 in the surveillance, epidemiology, and end results (SEER)-Medicare database, treated with either tamoxifen or an AI, and followed through December 31, 2012. To compare myocardial infarction (MI) risk for the treatment groups of AIs vs tamoxifen, we developed and assigned stabilized probability of treatment weights and used the Fine and Gray model for time to MI with death not related to MI as a competing risk. RESULTS: Of the cohort of 5648 women, 4690 were treated with AIs and 958 with tamoxifen; a total of 251 patients developed MI, and 22 patients died of MI during the study period while 476 died of other causes. The hazard for MI was not significantly different between AI vs tamoxifen groups (HR = 1.01, 95% CI 0.72-1.42), after adjusting for the following known MI risk factors at the start of adjuvant therapy: diabetes, ischemic heart disease, congestive heart failure, MI, and peripheral vascular disease. CONCLUSIONS: In this SEER-Medicare-based population study, there were no significant differences in the risk of MI between AI and tamoxifen users after adjustment for known risk factors.
BACKGROUND: Theoretically, the estrogen deprivation induced by aromatase inhibitors (AIs) might cause ischemic heart disease, but empiric studies have shown mixed results. We aimed to compare AIs and tamoxifen with regard to cardiovascular events among older breast cancerpatients outside of clinical trials. We hypothesized that AIs increase the risk of myocardial infarction. METHODS: We identified women age ≥67 years diagnosed with breast cancer from June 30, 2006 to June 1, 2008 in the surveillance, epidemiology, and end results (SEER)-Medicare database, treated with either tamoxifen or an AI, and followed through December 31, 2012. To compare myocardial infarction (MI) risk for the treatment groups of AIs vs tamoxifen, we developed and assigned stabilized probability of treatment weights and used the Fine and Gray model for time to MI with death not related to MI as a competing risk. RESULTS: Of the cohort of 5648 women, 4690 were treated with AIs and 958 with tamoxifen; a total of 251 patients developed MI, and 22 patients died of MI during the study period while 476 died of other causes. The hazard for MI was not significantly different between AI vs tamoxifen groups (HR = 1.01, 95% CI 0.72-1.42), after adjusting for the following known MI risk factors at the start of adjuvant therapy: diabetes, ischemic heart disease, congestive heart failure, MI, and peripheral vascular disease. CONCLUSIONS: In this SEER-Medicare-based population study, there were no significant differences in the risk of MI between AI and tamoxifen users after adjustment for known risk factors.
Authors: Susan R Heckbert; Charles Kooperberg; Monika M Safford; Bruce M Psaty; Judith Hsia; Anne McTiernan; J Michael Gaziano; William H Frishman; J David Curb Journal: Am J Epidemiol Date: 2004-12-15 Impact factor: 4.897
Authors: Alan S Coates; Aparna Keshaviah; Beat Thürlimann; Henning Mouridsen; Louis Mauriac; John F Forbes; Robert Paridaens; Monica Castiglione-Gertsch; Richard D Gelber; Marco Colleoni; István Láng; Lucia Del Mastro; Ian Smith; Jacquie Chirgwin; Jean-Marie Nogaret; Tadeusz Pienkowski; Andrew Wardley; Erik H Jakobsen; Karen N Price; Aron Goldhirsch Journal: J Clin Oncol Date: 2007-01-02 Impact factor: 44.544
Authors: Elena Birman-Deych; Amy D Waterman; Yan Yan; David S Nilasena; Martha J Radford; Brian F Gage Journal: Med Care Date: 2005-05 Impact factor: 2.983
Authors: Sharon H Giordano; Zhigang Duan; Yong-Fang Kuo; Gabriel N Hortobagyi; James S Goodwin Journal: J Clin Oncol Date: 2006-06-20 Impact factor: 44.544
Authors: Per E Lønning; Jürgen Geisler; Lars E Krag; Bjørn Erikstein; Yngve Bremnes; Anne I Hagen; Ellen Schlichting; Ernst A Lien; Erik S Ofjord; Jolanda Paolini; Anna Polli; Giorgio Massimini Journal: J Clin Oncol Date: 2005-06-27 Impact factor: 44.544
Authors: Henning Mouridsen; Aparna Keshaviah; Alan S Coates; Manuela Rabaglio; Monica Castiglione-Gertsch; Zhuoxin Sun; Beat Thürlimann; Louis Mauriac; John F Forbes; Robert Paridaens; Richard D Gelber; Marco Colleoni; Ian Smith; Karen N Price; Aron Goldhirsch Journal: J Clin Oncol Date: 2007-11-12 Impact factor: 44.544
Authors: Carrie N Klabunde; Julie M Legler; Joan L Warren; Laura-Mae Baldwin; Deborah Schrag Journal: Ann Epidemiol Date: 2007-05-25 Impact factor: 3.797
Authors: Heather Greenlee; Carlos Iribarren; Jamal S Rana; Richard Cheng; Mai Nguyen-Huynh; Eileen Rillamas-Sun; Zaixing Shi; Cecile A Laurent; Valerie S Lee; Janise M Roh; Margarita Santiago-Torres; Hanjie Shen; Dawn L Hershman; Lawrence H Kushi; Romain Neugebauer; Marilyn L Kwan Journal: J Clin Oncol Date: 2022-04-06 Impact factor: 50.717
Authors: Jaqueline S da Silva; Tadeu L Montagnoli; Bruna S Rocha; Matheus L C A Tacco; Sophia C P Marinho; Gisele Zapata-Sudo Journal: Int J Mol Sci Date: 2021-01-07 Impact factor: 5.923